|
Children 3 years to less than 10 years and adolescents <35 kg
|
Adolescents (10 to 19 years) ≥35 kg
|
---|
Preferred
|
ABCa + 3TC + EFV
|
TDF + 3TC (or FTC) + EFVa
|
Alternatives
|
ABC + 3TC + NVP
| |
|
AZT + 3TC + EFV
|
AZT + 3TC + EFV
|
|
AZT + 3TC + NVP
|
AZT + 3TC + NVP
|
|
TDF + 3TC (or FTC) + EFV
|
TDF + 3TC (or FTC) + NVP
|
|
TDF + 3TC (or FTC) + NVP
| |
Special circumstancesc
|
d4Tb + 3TC + EFV
|
ABC + 3TC + EFV
|
d4Tb + 3TC + NVP
|
ABC + 3TC + NVP
|
-
aThese recommendations apply to children and adolescents who are initiating first-line antiretroviral therapy; bd4T use should be restricted to situations in which toxicity to AZT is suspected or confirmed and access to ABC or TDF is lacking.
-
cSpecial circumstances may include situations where preferred or alternative regimens may not be available or suitable because of significant toxicities, anticipated drug-drug interactions, drug procurement and supply management issues, or for other reasons.
-
3TC lamivudine, ABC abacavir, AZT zidovudine, d4T stavudine, EFV efavirenz, FTC emtricitabine, LPV/r lopinavir/ritonavir, NVP nevirapine, TDF tenofovir, WHO World Health Organization.